Abbreviations & Acronyms ADT = androgen deprivation therapy bPSA = baseline prostatespecific antigen BST = best supportive care BT = brachytherapy CI = confidence interval CRPC = castration-resistant prostate cancer CRR = competing risks regression CRT = conformal radiation therapy CSM = cancer-specific mortality CSS = cancer-specific survival EBRT = external beam radiation therapy ePLND = extensive lymph node dissection HR = hazard ratio IMRT = intensity-modulated radiation therapy IPS = independent predictor status LOS = length of hospital stay LRT = locoregional treatment LT = local treatment mPCa = metastatic prostate cancer MVA = multivariable Cox regression models NCDB = National Cancer Database NLT = no local treatment NNT = number needed to treat OM = overall mortality OS = overall survival PCa = prostate cancer PCBaSE = National Prostate Cancer Registry of Sweden, Swedish Cancer Register and seven other national registers PD = progressive disease PFS = progression-free survival PS = propensity score Abstract: The potential oncological benefit for radical treatment in the setting of oligometastatic prostate cancer has been under investigation and is frequently discussed. We carried out a systematic review of English language articles using the Medline database (January 2000 to May 2017) to identify studies reporting local treatment in men with metastatic prostate cancer at diagnosis. Primary end-points were oncological outcomes, such as cancer-specific and overall mortality. Secondary end-points were non-oncological outcomes, such as complications, operating room time, blood loss or length of hospital stay. Two independent authors reviewed and extracted all search results. Overall, 18 studies reporting on local treatment in metastatic prostate cancer patients were identified (14 original articles, three brief correspondences and one letter to the editor). All of them were retrospective; one partly included prospective data. All studies addressed oncological outcomes, 16 compared local treatment with no-local treatment and 14 adjusted for confounders using multivariable regression models. All but one study concluded a survival benefit for local treatment in the metastatic setting. Due to heterogeneity of available data, a representative meta-analysis could not be carried out. Five studies reported nononcological outcomes. Although local treatment in metastatic prostate cancer appears to be feasible, its oncological effect remains unclear due to high susceptibility of available studies to significant selection bias.
Abbreviations & Acronyms ADT = androgen deprivation therapy bPSA = baseline prostatespecific antigen BST = best supportive care BT = brachytherapy CI = confidence interval CRPC = castration-resistant prostate cancer CRR = competing risks regression CRT = conformal radiation therapy CSM = cancer-specific mortality CSS = cancer-specific survival EBRT = external beam radiation therapy ePLND = extensive lymph node dissection HR = hazard ratio IMRT = intensity-modulated radiation therapy IPS = independent predictor status LOS = length of hospital stay LRT = locoregional treatment LT = local treatment mPCa = metastatic prostate cancer MVA = multivariable Cox regression models NCDB = National Cancer Database NLT = no local treatment NNT = number needed to treat OM = overall mortality OS = overall survival PCa = prostate cancer PCBaSE = National Prostate Cancer Registry of Sweden, Swedish Cancer Register and seven other national registers PD = progressive disease PFS = progression-free survival PS = propensity score Abstract: The potential oncological benefit for radical treatment in the setting of oligometastatic prostate cancer has been under investigation and is frequently discussed. We carried out a systematic review of English language articles using the Medline database (January 2000 to May 2017) to identify studies reporting local treatment in men with metastatic prostate cancer at diagnosis. Primary end-points were oncological outcomes, such as cancer-specific and overall mortality. Secondary end-points were non-oncological outcomes, such as complications, operating room time, blood loss or length of hospital stay. Two independent authors reviewed and
Introduction
PCa is the most commonly diagnosed cancer type, and the second and third leading cause of cancer death among men in the USA and in Europe, respectively. 1 The median survival for patients with de novo mPCa is approximately 3-4 years. 1 LT with RP or RT in addition to ADT in patients with mPCa has been reported to carry a survival benefit and has recently gained more attention. Potential benefits can include improved local tumor control and decreased necessity for subsequent palliative therapies. Furthermore, treatment of the primary tumor might have the potential to change the further course of the disease. These potential benefits must be weighted against potential risks associated with surgery and radiotherapy in this setting. Randomized trials addressing this topic are recruiting, but results are currently pending.
The aim of the present systematic review was to summarize data from studies reporting on LT in men with de novo mPCa. Primary end-points were oncological outcomes, such as CSM and OM. Secondary end-points were non-oncological outcomes, such as complications, operating room time, blood loss or LOS. 
Methods
Eligibility criteria, search strategy and study selection
We carried out a systematic review based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses criteria, searching Medline for original English language articles and studies published between January 2000 and June 2017. 2 Additional sources, such as reference lists of included studies, and personal communications complemented the search. Key words used are shown in Figure S1 .
Types of study designs and participants included
In the absence of RCTs, all original articles and brief correspondences, as well as editorial comments and letters to the editor were considered. The study population was limited to patients with de novo mPCa across all ages.
Outcome measurements
Primary end-points were oncological outcomes, namely, CSM and OM among patients who underwent RP or RT compared with their NLT counterparts. We further included studies that focused on biochemical recurrence, CR and development of castration-resistant mPCa. Secondary end-points were feasibility of RP or RT in the metastatic setting. Therefore, complications and toxicity were assessed as overall rates or grades of severity (Clavien-Dindo classification system, European Organization for Research and Treatment of Cancer criteria, Common Terminology Criteria for Adverse Events version 4.0). Further intra-and postoperative outcomes included operating room time, blood loss, LOS, catheterization time and urinary continence.
Data analysis
All titles, abstracts and full text articles were screened by two independent reviewers (RSP and DT). In case of disagreement, a third party (MB or MM) was contacted. Data extraction was carried out using the Participants, Interventions, Comparators, Outcomes and Study Design approach. Therefore, a data extraction form to collect relevant data among all available studies was created for both primary and secondary end-points (Tables 1,2) . Specifically, two independent reviewers (RSP and DT) extracted all information on study design, study cohort, type of intervention and end-points. Because of the vast heterogeneity in the available literature and the limited amount of databases that were used, representative meta-analyses could not be carried out. However, for better visualization, we present HRs among different studies that reported multivariable regression analyses predicting CSM and OM using forest plots (Fig. 1a,b ). Plots were created for each treatment type (RP or RT) and primary outcomes (CSM or OM). It is of note that these plots show raw HR without weighting.
Results

Quantity of evidence identified
A total of 2486 studies were identified. After title and abstract screening, 110 studies remained for full text assessment. Of those, 11 original articles, three brief correspondences and one letter to the editor were finally included into the present review. Furthermore, we included one unpublished study that is currently in submission.
Characteristics of studies included
None of the identified studies were RCTs. All available data were retrospective. One study partly included prospective data. Overall, five studies relied on the SEER database, one on the SEERMedicare, three on the NCDB, one on the Munich Cancer Registry and one on the PCBaSE (Table 1) . Additional two studies reported multicenter results, and further five studies reported single institutional results. All 18 studies examined survival of locally-treated mPCa patients and 16 compared different types of LT with NLT. Of those, 14 provided multivariable models that were adjusted for potential confounders. Seven carried out propensity score matching to further adjust for differences among the LT and NLT groups. CSM was the primary end-point in six studies, OM in eight and four focused on both end-points. Furthermore, four studies reported other oncological outcomes biochemical recurrence, CR, castration resistance). Non-oncological outcomes were assessed in six studies, including five reporting the results of RP and one of RT (Table 2) .
Studies reporting oncological outcomes
Culp et al. were the first to utilize data on oncological outcomes after LT of de novo mPCa from the SEER database, which encompasses population-based cancer registries covering approximately 28% of the USA population and where most of the available studies on this topic stem from. [3] [4] [5] [6] A total of 8185 patients who received NLT (n = 7811), RP (n = 245) or BT (n = 129) were analyzed. The 5-year OS and predicted disease-specific survival were each significantly higher in patients undergoing RP (67.4% and 75.8%, respectively) or BT (52.6% and 61.3%, respectively) compared with NLT (22.5% and 48.7%, respectively, P < 0.001). Furthermore, undergoing RP or BT was each independently associated with decreased CSM (P < 0.01). 4 In a further analysis from the same database, Fossati et al. assessed whether the benefit of LT was dependent on baseline risk by testing an interaction with CSM risk and LT. To calculate CSM risk at 3 years, a predictive model was used, consisting of age at diagnosis, PSA level, Gleason score (categorized as ≤6, 7 or ≥8), T stage (T2 or lower vs T3 or higher), N stage (N0/Nx vs N1) and M stage (categorized as M1a, M1b or M1c). The authors observed that LT conferred a survival benefit at 3 years after diagnosis only in patients with a CSM risk <40%. When CSM risk exceeded 50%, LT did not provide a survival benefit. 5 Recently, Leyh-Bannurah et al. updated the data from the SEER database after a median follow-up period of 43.5 months for patients with LT, and 31 months for patients with NLT. 6 The authors additionally provided propensity score matching with adjustment variables consisting of age, race, biopsy Gleason score, clinical tumor stage, nodal stage and metastatic substages. Furthermore, the authors compared RP with RT. Of 13 692 mPCa patients included in the study, 474 received LT (313 underwent RP and 161 RT). In propensity score-matched MVA CRR analyses, both LT types, RP and RT, were associated with lower CSM rates (65% and 52%, respectively) relative to NLT (SHR 0.35, 95% CI 0.26-0.46 and SHR 0.48, 95% CI 0.35-0.66, both P < 0.001). 6 In propensity score-matched MVA CRR testing RP versus RT, the RP group showed lower CSM (41%) when compared with RT (SHR 0.59, 95% CI 0.35-0.99, P = 0.048).
Limitations of all studies based on the SEER database that were described above are manifold. The SEER database lacks important variables that are indispensable to control for selection bias. These variables include comorbidities and/or performance status, number, size and site of metastases (only M substages), timing and dosage of ADT, chemotherapy and/or new agents, as well as site-specific EBRT codes, which precluded examining the effects of IMRT or other forms of prostate-directed EBRT on patient survival and only allow analysis of brachytherapy codes. In addition, bPSA values were only documented for a subgroup of patients from the SEER database, and post-ADT PSA were not available. These, however, are prognostic markers and most likely have been used to choose for LT. Finally, findings have not been evaluated in an M substage-specific fashion.
The limitation of the lack of sufficient bPSA data has most recently been addressed by our group. 7 We complemented the results of Leyh-Bannurah et al. by using the latest SEER database release, which provides validated bPSA values from 2004 onwards that were previously unavailable. We tested whether LT (RP or BT) still conferred a survival benefit compared with NLT, even when adjusted for bPSA, and further analyzed whether the effect of LT might be modulated according to bPSA and M1 substages. 7 In M1b patients, lower bPSA values resulted in higher survival benefit, when LT was compared with NLT, up to a threshold of 60 ng/mL. No survival benefit was observed in M1b patients above the 60 ng/mL PSA threshold and in M1c patients, regardless of bPSA.
Satkunasivam et al. retrospectively analyzed data from the SEER-Medicare database. The linkage of the SEER registry to Medicare offers additional treatment data, including therapies such as ADT that are administered in the outpatient setting in patients aged >65 years. Of 4069 men with de novo mPCa included in the study, 47 patients received RP, 88 IMRT, 107 conformal radiation therapy and 3827 NLT. RP was associated with a 52% decrease in the risk of CSM (HR 0.48, 95% CI 0.27-0.85, P = 0.01) after adjusting for sociodemographics, primary tumor characteristics, comorbidity, ADT and bone radiation within 6 months of diagnosis. IMRT was associated with a 62% decrease in the risk of CSM (HR 0.38, 95% CI 0.24-0.61, P < 0.001), whereas conformal radiation treatment was not associated with improved oncological outcome. 8 This cohort consisted of men aged >65 years, and the results might not be generalizable. Furthermore, the main limitation of selection bias remains.
Three studies used data from the NCDB, a hospital-based cancer registry that collects data from American College of Surgeons-Commission on Cancer accredited facilities, to evaluate the OS of men with mPCa treated with ADT with and without LT. [9] [10] [11] Rusthoven et al. reported data of 6382 men with newly diagnosed mPCa including 538 (8.4%) receiving prostate RT from 2004 to 2012. 11 The authors showed an overall survival benefit through the addition of RT to ADT for these patients on both univariable and multivariable analysis (HR 0.62, 95% CI 0.55-0.71, P < 0.001) adjusted for age, year, race, comorbidity score, bPSA level, Gleason score, T stage, N stage, chemotherapy administration, treating facility and insurance status. In a secondary analysis comparing the survival outcomes for patients treated with RT plus ADT versus prostatectomy plus ADT, the authors did not find significant differences in OS, whereas both therapies were superior to ADT alone. 11 Subgroup analyses from that study showed a greater benefit with prostate RT among patients with Gleason scores ≤8 and T1-3 (vs T4) tumors. A propensity score analysis was carried out matching 537 patients receiving prostate RT and ADT with 537 patients receiving ADT alone that also showed superior median (55 vs 37 months) and 5-year OS (49% vs 33%) with prostate RT plus ADT (P < 0.001), which, however, was attenuated compared with the survival advantage observed with prostate RT in the overall cohort. This confirms the importance of accounting for differences in baseline characteristics.
Similarly, L€ oppenberg et al. analyzed a total of 15 501 patients with mPCa from the NCDB from 2004 to 2012 that were categorized in LT (RP or RT targeted to prostate) versus NLT. 9 Overall, 9.5% of the patients received LT. Consistent with previous retrospective data, the authors found that patients receiving LT had better 3-year OS rates compared with their NLT counterparts (69% vs 54%, P < 0.001). Furthermore, the authors found the impact of LT on OM to be highly influenced by tumor and patient characteristics, where patients with the lowest predicted OM risk benefited the most from LT. 9 Compared with SEER reports, the data from NCDB included all age categories and comorbidity status, and excluded patients treated with palliative intent. Despite this, limitations in the NCDB-based reports remain manifold. First and foremost, all conclusions are gathered from retrospective studies with their inherent selection bias. Parikh et al., who published the most recent report from NCDB data on local therapy in mPCA, confirmed this limitation by showing that the use of LT was associated with younger age (≤70 years), lower comorbidity score, lower T stage, Gleason score <8, node-negative status, private and Medicare insurance, higher income quartile, and treatment at comprehensive or academic programs (P < 0.05). 10 Information on performance status, and the extent and site of metastatic disease burden were not available beyond surrogates, such as age, comorbidities, PSA and pathological characteristics. Furthermore, data on the type and duration of systemic or salvage therapies were lacking.
Several single institutional retrospective studies have provided their data on LT in de novo mPCa, and conformingly reported improved survival among patients with mPCa treated with LT. [12] [13] [14] [15] [16] A retrospective multi-institutional case series from 2007 to 2014 comprising 106 patients with newly diagnosed mPCa from the USA, Germany, Italy and Sweden who underwent RP showed an OM rate of 11.3% at a median follow-up period of 22.8 months. 17 Data from the Munich Cancer Registry reported similar improvements in OS among 74 of 1538 (5%) men with mPCa treated with RP. 18 However, conclusions from this report are not possible, as multivariable analyses were not carried out, and no data were available on performance status, comorbidity, site-specific external beam radiation therapy, extent of bone metastasis and further treatments.
Recently, Sooriakumaran et al. presented data from the PCBaSe Sweden, a population-based dataset of the National Prostate Cancer Registry of Sweden, the Swedish Cancer Register and seven other national registers. 19 A total of 17 602 patients treated with ADT were compared with 750 radically-treated (RT n = 630 or RP n = 120) patients who were classified as being at high risk of disseminated PCa. In the matched cohort, CSM reached >50% by 14 years in the ADT group compared with 25% in the corresponding radically-treated group. Information on comorbidities was available, but limitations included the lack of information on secondary treatments and heterogeneity of the patient cohort, with large localized/locally advanced tumors, as well as the lower end of the metastatic spectrum because of the use of PSA >50 to identify men at high risk of disseminated PCa. Many men were labeled as Mx, and combining these with mPCA patients could have introduced a bias. 19 Currently, several RCTs are addressing the survival impact of prostate RT or RP in addition to ADT or best systemic therapy in the metastatic setting (e.g. NCT00268476; NCT01957436;
NCT02454543, NCT02458716 and NCT01751438). However, the trials are currently ongoing and results are pending. Therefore, we have to rely on registry or institutional data at this point.
To circumvent the major limitation of potential selection bias from previous retrospective studies, where healthier, asymptomatic patients with lower metastatic burden are more likely to be selected for LT, Steuber et al. combined data from two centers. 20 The data of the LT group (RP n = 43) were prospectively collected in a single institution (partly within a single-arm clinical trial), whereas the patients in the NLT group (with BST n = 40) were extracted from the database of the Copenhagen Prostate Cancer Center, which did not offer LT in mPCa during the study period, using the same inclusion criteria as for patients in the LT group. Interestingly, the authors did not find a difference in castrationresistant free survival (P = 0.92) or OS (P = 0.25) within a median follow-up period of 32.7 months in the LT group and 82.2 months in the NLT group. 20 That study, which aimed to reduce the risk of selection bias, represents the first to show no positive impact of LT on oncological outcomes and thus is in contrast to all the existing studies. However, the shorter follow-up period in the LT group represents the main limitation of the brief correspondence. The differing results underline the lack of high-quality evidence and the necessity of randomized trials.
Studies reporting non-oncological outcomes
Several studies have addressed the feasibility and non-oncological outcomes of cytoreductive RP, which have been summarized in Table 2. 13-17, 20 Heidenreich et al. presented a feasibility and case-control study showing that cytoreductive RP was feasible and did not increase surgery-related complications in well-selected patients. 15 RP was carried out in 23 patients with one to three hot spots in bone scans, but without visceral and extensive lymph node metastases, in whom a PSA decrease to <1.0 ng/mL after neoadjuvant ADT was achieved.
In their multi-institutional study with 106 de novo mPCa patients, Sooriakumaran et al. showed safety of RP in expert hands. 17 Here, 79.2% of the patients did not have any complications. Blood transfusions were given to 15 of 106 (14.2%) patients, nine of 106 (8.5%) had lymphoceles, seven of 106 (6.6%) had anastomotic leaks and five of 106 (4.7%) had wound infections. Of those who had complications, six of 22 (27.3%) had two complications. 17 Steuber et al. compared complications of the LT (RP) versus NLT group. 20 Just three of 43 patients (7.0%) in the RP group experienced local complications (two surgery-related anastomotic strictures and one patient with severe incontinence requiring further intervention) compared with 35% in the BST group.
Conclusions
Retrospective data from a handful of databases have shown a survival benefit by the addition of local treatment to ADT in men with de novo mPCa, whereas one study including prospective data did not confirm this result. Study designs, definition of end-points and quality of analyses were highly heterogeneous. In light of these limitations, it was not possible to create a representative meta-analysis and all presented data remain purely descriptive.
Limitations of the studies were manifold, including missing information on comorbidities, performance status, secondary treatments, timing and dosage of ADT, as well as bPSA and post-ADT PSA, among others. Some studies completely lacked multivariable analyses. Furthermore, most populationbased studies lacked information on metastatic burden. Patients were categorized into M1a, M1b or M1c, while, for example, the number of bone lesions was unknown, but likely played an important role.
Included studies compared highly selected mPCa patients (between 3.5% and 13.7% of the study populations) that underwent LT to mostly unselected NLT mPCa patients. This said, even though some studies applied propensity score adjustment, the results remain biased from unmeasured confounding variables and should be interpreted with caution. Men with localized PCa undergoing surgery have better longterm OS than the general population of men without cancer, clearly showing how men who are considered surgical candidates have better overall health.
Currently, several RCTs are addressing the survival impact of prostate RT or RP in addition to ADT or best systemic therapy in the metastatic setting (e.g. NCT00268476; NCT01957436; NCT02454543, NCT02458716 and NCT01751438). Without results of these, the role of LT in the metastatic setting cannot be conclusively answered.
